Abstract

To identify novel oncogenic targets in head and neck squamous cell carcinoma (HNSCC), we have analyzed antitumor microRNAs (miRNAs) and their controlled molecular networks in HNSCC cells. Based on our miRNA signature in HNSCC, both strands of the miR-99a-duplex (miR-99a-5p: the guide strand, and miR-99a-3p: the passenger strand) are downregulated in cancer tissues. Moreover, low expression of miR-99a-5p and miR-99a-3p significantly predicts poor prognosis in HNSCC, and these miRNAs regulate cancer cell migration and invasion. We previously showed that passenger strands of miRNAs have antitumor functions. Here, we screened miR-99a-3p-controlled oncogenes involved in HNSCC pathogenesis. Thirty-two genes were identified as miR-99a-3p-regulated genes, and 10 genes (STAMBP, TIMP4, TMEM14C, CANX, SUV420H1, HSP90B1, PDIA3, MTHFD2, BCAT1, and SLC22A15) significantly predicted 5-year overall survival. Notably, among these genes, STAMBP, TIMP4, TMEM14C, CANX, and SUV420H1 were independent prognostic markers of HNSCC by multivariate analyses. We further investigated the oncogenic function of STAMBP in HNSCC cells using knockdown assays. Our data demonstrated that the aggressiveness of phenotypes in HNSCC cells was attenuated by siSTAMBP transfection. Moreover, aberrant STAMBP expression was detected in HNSCC clinical specimens by immunohistochemistry. This strategy may contribute to the clarification of the molecular pathogenesis of this disease.

Highlights

  • Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer, with approximately 650,000 new cases diagnosed annually and 400,000 head and neck squamous cell carcinoma (HNSCC)-related deaths worldwide each year [1]

  • We focused on miR-99a-5p and miR-99a-3p based on our HNSCC miRNA signature determined by RNA sequencing [20]

  • Cohort analysis using data from The Cancer Genome Atlas (TCGA) database revealed that low expression of miR-99a-5p and miR-99a-3p was associated with poorer survival in patients with HNSCC

Read more

Summary

Introduction

Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer, with approximately 650,000 new cases diagnosed annually and 400,000 HNSCC-related deaths worldwide each year [1]. Cells 2019, 8, 1535 prognosis [1,4] owing to recurrence, metastasis, and treatment resistance [5]. The median overall survival time for patients with recurrence and metastasis is 10–13 months in the setting of first-line chemotherapy and 6 months in the second-line setting [6]. Epidermal growth factor receptor inhibitors and immune checkpoint inhibitors have emerged as therapeutic approaches in HNSCC treatment [7,8]. These treatments do not yield satisfactory results

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call